Evidence map›Paper›PMID 39242159›Full record

ArticleBMJ open2024

Unveiling the prevalence of anaemia and its predictors among adults on highly active antiretroviral therapy in the dolutegravir era: a retrospective cross-sectional study.

Woretaw Sisay Zewdu, Mulugeta Molla Zeleke, Yared Andargie Ferede, Achenef Bogale Kassie, Pradeep Singh, Muluken Adela Alemu, Getaye Tessema Desta

Abstract read
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Woretaw Sisay ZewduSchool of Pharmacy Department of Pharmacology and Toxicology, Debre Tabor University, Debre Tabor, Ethiopia sisayworetaw@gmail.com.ORCID 0000-0003-2616-4014
Mulugeta Molla ZelekeSchool of Pharmacy Department of Pharmacology and Toxicology, Debre Tabor University, Debre Tabor, Ethiopia.
Yared Andargie FeredeSchool of Pharmacy Department of Pharmacology and Toxicology, Debre Tabor University, Debre Tabor, Ethiopia.
Achenef Bogale KassieSchool of Pharmacy Department of Pharmacology and Toxicology, Debre Tabor University, Debre Tabor, Ethiopia.ORCID 0000-0003-4697-7303
Pradeep SinghDepartment of Pharmaceutical Chemistry, Debre Tabor University, Debre Tabor, Ethiopia.
Muluken Adela AlemuSchool of Pharmacy Department of Pharmacology and Toxicology, Debre Tabor University, Debre Tabor, Ethiopia.
Getaye Tessema DestaSchool of Pharmacy Department of Pharmacology and Toxicology, Debre Tabor University, Debre Tabor, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study examined the prevalence, severity and risk factors of anaemia among adult people living with HIV attending an antiretroviral therapy centre in Woreta Primary Hospital, Woreta town, Ethiopia.

designHospital-based retrospective cross-sectional study.

settingPublic health facility that provides HIV care in Woreta town.

participantsA total of 289 medical records of adults living with HIV/AIDS on highly active antiretroviral therapy from February 2019 to September 2023 at government hospital were reviewed using a systematic sampling method. The data were entered using Epi-info V.7 and exported to SPSS V.23 for data analysis. The data were analysed using bivariate and then multivariate logistic regression models in order to identify variables associated with anaemia. At the 95% CI level, variables having a p value of <0.05 were deemed to be statistically significant predictors. PRIMARY OUTCOME: Prevalence and severity of anaemia and its predictors among adult patients living with HIV on antiretroviral therapy in Woreta Primary Hospital.

resultsThe total prevalence of anaemia was 31.5% (95% CI 28.9 to 33.8). The prevalence of mild, moderate and severe anaemia was 20.42%, 10.38% and 0.70%, respectively. Predictors independently linked with anaemia were female sex (adjusted OR (AOR) 1.08), age ≥40 years (AOR 1.21), lived with HIV >10 years (AOR 2.31), CD4 counts <200 cells/µL (AOR 3.81), non-suppressed viral load (AOR 1.28), history of opportunistic infections (AOR 1.54), WHO clinical stages III and IV (AOR 1.37 and 2.23, respectively) and history of parasitic infestation (AOR 2.81).

conclusionsA sizeable proportion of participants were found anaemic. Female sex, older age, longer periods lived with the virus, lower CD4 count, non-suppressed viral load, history of opportunistic infections, WHO clinical stages III and IV and history of parasitic infestation were the contributing factors. Therefore, to improve the anaemic status and living circumstances of patients living with HIV, immediate action on the linked factors is needed, such as monitoring for maintenance of CD4 counts >200 cells/μL and avoiding progression of HIV to the advanced WHO clinical stages, suppressed viral load, preventing opportunistic infections and parasitic infestation.

Indexed as

AnemiaAntiretroviral Therapy, Highly ActiveHeterocyclic Compounds, 3-RingHIV InfectionsOxazinesPyridonesAdultCD4 Lymphocyte CountCross-Sectional StudiesDolutegravirEthiopiaFemaleHIV Integrase InhibitorsHumansMaleMiddle AgedDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridonesanaemiaHIV & AIDSinfectious disease/HIVprevalencerisk factors

Identifiers

PMID39242159
PMCPMC11590816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.